Search results
Found 29702 matches for
New partnership with Johnson & Johnson Innovative Medicine announced
13 February 2025
The Translational Pharmacology Group, led by James Fullerton at NDORMS, has announced a significant new partnership with Johnson & Johnson Innovative Medicine to leverage their human experimental medicine platform.
Pancreatic cancer immune map provides clues for precision treatment targeting
7 February 2025
Study shows why there are differences in prognosis between different pancreatic tumours and identifies potential avenues for improved treatment approaches.
New theory explains reporting of suspected adverse drug reactions to biological therapies used in rheumatology care
4 February 2025
A recent study introduces "Pragmatic Situational Practice Outcomes," shedding light on the complexities affecting how patients and healthcare professionals report suspected ADRs related to biologic medications.
Stephanie Dakin awarded a Versus Arthritis Bridging Fellowship
29 January 2025
Professor Stephanie Dakin has been awarded a Versus Arthritis Bridging Fellowship to advance the work of her Versus Arthritis sponsored Career Development Fellowship investigating frozen shoulder.
An interview with Audrey Gerard
21 January 2025
Audrey Gerard, an Associate Professor of Immune Cell Dynamics and Principal Investigator at the Kennedy Institute of Rheumatology, is working to understand how the immune response interacts with and shapes tumours.
Professor Michael Dustin named AAI Distinguished Fellow
20 January 2025
The American Association of Immunologists (AAI) has recognised the outstanding work of the Kennedy Institute’s Professor of Molecular Immunology Michael Dustin by naming him a Distinguished Fellow of AAI.
Laura Coates becomes the first rheumatologist to receive prestigious NIHR professorship
9 January 2025
The first ever rheumatologist to be awarded an NIHR Research Professorship, Laura will use the funding to further her research into psoriasis and psoriatic arthritis aiming to transform patient care and treatment personalisation.
How an 'optional' amino acid is required for an optimal immune response
3 January 2025
A new study conducted by researchers at the Kennedy Institute of Rheumatology has uncovered a pivotal role of asparagine metabolism in regulating B cell homeostasis and immune response.
James Fullerton awarded a British Pharmacological Society Fellowship
17 December 2024
Associate Professor James Fullerton has been awarded Fellowship of the British Pharmacological Society (BPS) following a recommendation by their Honors and Fellows Panel, recognising his sustained contribution to the discipline of Clinical Pharmacology and Therapeutics.
Paul Kubes joins the Kennedy Institute as the Newton-Abraham Visiting Professor
9 December 2024
Paul joined the Kennedy Institute in September 2024 as part of the Newton-Abraham Visiting Professorship, a prestigious award given by the University of Oxford to the most distinguished scholars in the biological, chemical or medical sciences.
Machine learning outperforms surgeons in predicting knee replacement outcomes
5 December 2024
A new study has revealed that machine learning models can significantly outperform experienced surgeons in predicting patient outcomes after partial knee replacement.
NDORMS study highlights lingering symptoms long after COVID-19 infection
15 November 2024
A new international study has shed light on the significant burden of post-acute COVID-19 symptoms across N. America, Europe and Asia.
Oxford space lab experiment heads to International Space Station
5 November 2024
The first human tissue samples from Oxford's Space Innovation Lab (SIL) have been launched and are on their way to the International Space Station, where they will be used to study the effects of space microgravity on the human ageing process.
The Oxford EMCRF launches new bone marrow biopsy capability to expand research support
4 November 2024
The NIHR Oxford Clinical Research Facility (EMCRF) has expanded its support of medical research trials by offering bone marrow biopsies for the first time.
New co-directors of the taught MSc in Musculoskeletal Sciences announced
1 November 2024
NDORMS is pleased to announce the appointment of Sarah Snelling and Antony Palmer as the new co-Directors of the two-year, part-time MSc in Musculoskeletal Sciences.
Post-acute infection syndrome is not unique to COVID-19
25 October 2024
Patients hospitalised with COVID-19 often report a wide range of symptoms months after their initial illness. But a new study from NDORMS shows that post-acute infection syndrome (PAIS) is not unique to COVID-19 and can also occur after other respiratory infections.
Cellular roadmap reveals new paths to treating inflammatory bowel disease
22 October 2024
In a world first, researchers at the Kennedy Institute, Oxford have mapped the cellular dynamics following treatment with the most commonly used advanced therapy in autoimmune diseases. They have discovered why some patients benefit from this therapy while others do not, potentially paving the way for new therapies.
New MSc course comes to NDORMS
22 October 2024
The MSc in Experimental and Translational Therapeutics (ETT) is moving to NDORMS. Jointly run with the Department of Continuing Education, the move will expand the already broad range of disciplines covered in the course.